Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabigerolic acid (CBGA) is a non-psychoactive cannabinoid precursor found in Cannabis sativa. While CBGA has not been traditionally used in herbal medicine for inflammatory bowel disorders (IBD), there is emerging preclinical scientific evidence supporting its potential role. Several in vitro and animal studies have explored the anti-inflammatory properties of CBGA and related cannabinoids. For example, a 2018 study published in Biochemical Pharmacology demonstrated that CBGA reduced the expression of pro-inflammatory cytokines in cell models of inflammation. Furthermore, a 2021 study in Frontiers in Pharmacology found that CBGA and other acidic cannabinoids could modulate inflammatory pathways relevant to IBD pathogenesis, such as the NF-κB signaling pathway.

Despite these promising laboratory findings, there is currently a lack of high-quality clinical trials evaluating the efficacy and safety of CBGA in humans with IBD, such as Crohn’s disease or ulcerative colitis. Most available data are from cell-based assays or animal models, which may not translate directly to human disease. Therefore, while scientific interest and preliminary preclinical evidence exist, clinical validation is still lacking. The evidence strength is therefore rated as 2 out of 5, reflecting encouraging but still early-stage research.

More about Cannabigerolic acid
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Cannabigerolic acid

Products containing Cannabigerolic acid